Blab Business
EssilorLuxottica Shares Tumble 30% Amid Expansion into MedTech and Hearing Solutions
EssilorLuxottica SA (ticker EL on Euronext Paris) has fallen almost 30% in the last twelve months, dropping to around €140 from a year‑earlier peak of €200. The decline comes as the company reports continued profitable growth while investing heavily in three new growth pillars—myopia management, smart eyewear and integrated hearing aids—that are currently eroding margins.
The Franco‑Italian eyewear giant, formed by the 2018 merger of Essilor and Luxottica, posted record revenue of €28.5 billion in 2025, up 11% at constant currency. The fourth quarter alone saw an 18% rise, driven by strong sales of prescription lenses and branded eyewear. Despite the revenue lift, the company’s forward price‑to‑earnings ratio has compressed to 22×, below the 10‑year average, reflecting market expectations of tighter margins.
EssilorLuxottica’s strategy to broaden its addressable market has focused on three sectors that promise long‑term upside but require upfront investment. Myopia management involves digital tools and optical products aimed at slowing the progression of nearsightedness, especially in children. Smart eyewear includes augmented‑reality glasses and connected lenses that collect data for health and lifestyle applications. Integrated hearing aids combine audio enhancement with vision care, targeting an aging population that increasingly seeks multimodal solutions.
"These initiatives expand our portfolio beyond traditional lenses and frames," said a company spokesperson in a statement released in June 2026. "They also position us to capture new revenue streams as consumer expectations evolve," the spokesperson added.
Financially, the company maintains a dividend yield of 2.4% supported by robust free cash flow. In 2026, EssilorLuxottica paid a dividend in shares, issuing 957,954 new shares—about 0.21% of the company’s capital—after 41.9 million rights were exercised in favour of the 2025 dividend payment.
Share buyback activity has also been a key component of the company’s capital‑allocation policy. A buyback program launched in September 2022 allowed the firm to purchase up to 1.5 million shares, contingent on market conditions, and was scheduled to run through March 2023. The program was described by the company as a sign of confidence in its long‑term value creation.
The stock’s performance has been closely watched by investors in the broader CAC 40 and Euro Stoxx 50 indices, where EssilorLuxottica is a constituent. Analysts note that the company’s high growth expectations are now under pressure from increased competition in the eyewear and medtech markets, as well as from rising input costs.
Looking ahead, EssilorLuxottica is set to release its next earnings report on July 28 2026. The market will be watching for guidance on the profitability of the new growth pillars, the pace of the share‑buyback program, and any adjustments to the dividend policy.
In summary, EssilorLuxottica’s share price decline reflects the market’s assessment that the company’s expansion into myopia management, smart eyewear and hearing aids is currently suppressing profitability. The firm remains profitable and continues to generate strong free cash flow, which supports its dividend and buyback initiatives. Investors will be keen to see how the company balances investment in new business lines with the need to protect margins in the coming earnings cycle.
The Franco‑Italian eyewear giant, formed by the 2018 merger of Essilor and Luxottica, posted record revenue of €28.5 billion in 2025, up 11% at constant currency. The fourth quarter alone saw an 18% rise, driven by strong sales of prescription lenses and branded eyewear. Despite the revenue lift, the company’s forward price‑to‑earnings ratio has compressed to 22×, below the 10‑year average, reflecting market expectations of tighter margins.
EssilorLuxottica’s strategy to broaden its addressable market has focused on three sectors that promise long‑term upside but require upfront investment. Myopia management involves digital tools and optical products aimed at slowing the progression of nearsightedness, especially in children. Smart eyewear includes augmented‑reality glasses and connected lenses that collect data for health and lifestyle applications. Integrated hearing aids combine audio enhancement with vision care, targeting an aging population that increasingly seeks multimodal solutions.
"These initiatives expand our portfolio beyond traditional lenses and frames," said a company spokesperson in a statement released in June 2026. "They also position us to capture new revenue streams as consumer expectations evolve," the spokesperson added.
Financially, the company maintains a dividend yield of 2.4% supported by robust free cash flow. In 2026, EssilorLuxottica paid a dividend in shares, issuing 957,954 new shares—about 0.21% of the company’s capital—after 41.9 million rights were exercised in favour of the 2025 dividend payment.
Share buyback activity has also been a key component of the company’s capital‑allocation policy. A buyback program launched in September 2022 allowed the firm to purchase up to 1.5 million shares, contingent on market conditions, and was scheduled to run through March 2023. The program was described by the company as a sign of confidence in its long‑term value creation.
The stock’s performance has been closely watched by investors in the broader CAC 40 and Euro Stoxx 50 indices, where EssilorLuxottica is a constituent. Analysts note that the company’s high growth expectations are now under pressure from increased competition in the eyewear and medtech markets, as well as from rising input costs.
Looking ahead, EssilorLuxottica is set to release its next earnings report on July 28 2026. The market will be watching for guidance on the profitability of the new growth pillars, the pace of the share‑buyback program, and any adjustments to the dividend policy.
In summary, EssilorLuxottica’s share price decline reflects the market’s assessment that the company’s expansion into myopia management, smart eyewear and hearing aids is currently suppressing profitability. The firm remains profitable and continues to generate strong free cash flow, which supports its dividend and buyback initiatives. Investors will be keen to see how the company balances investment in new business lines with the need to protect margins in the coming earnings cycle.
